Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 62 of 65 · 3077 articles
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the...
People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...
Patients and clinicians following new, non‑immunosuppressive approaches to UC may be interested because MB310 is an oral live‑biotherapeutic designed to induce remission and is entering clinical testing.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
The study suggests a surgical change—removing the mesentery during Crohn’s operations—may significantly reduce early recurrence in the intestinal lining, which could mean fewer repeat surgeries and hospital readmissions...
Cure8 found this source from businesswire.com, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.
This study maps what researchers have been publishing about Crohn's disease in children over the past decade, highlighting major topics, influential papers, and active authors/institutions.
Some people with Crohn’s have ongoing GI symptoms despite little visible inflammation. This study suggests the gut microbiome—particularly sulfur-producing bacteria—may be a reason, and diet could be a potential target...
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.
New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...
A surgical technique (mesentery removal) reported in an international randomized trial lowered early endoscopic recurrence after Crohn’s surgery. If validated more widely, it could reduce repeat operations and hospital...
Arthralgia and other extraintestinal symptoms may signal higher risk of developing peripheral arthritis in people with Crohn disease. Recognizing early joint pain could prompt closer monitoring or earlier rheumatology...
Early Phase 2 data suggest VTX958 may improve endoscopic healing and lower inflammatory markers in Crohn’s disease, outcomes that matter for long-term disease control. The report also notes the trial missed its primary...
This reports Phase 2 clinical data for an oral TYK2 inhibitor (VTX958) in Crohn’s disease — a potential new oral treatment approach. The drug showed meaningful endoscopic improvements and reductions in inflammatory...
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.
Cure8 found this source from gut.bmj.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
This announcement signals growing clinical and preclinical data for obefazimod, an investigational IBD drug; it includes a preclinical report on anti-fibrotic activity, a complication important in Crohn’s disease.
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from alphagalileo.org.
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from miragenews.com.
If you have IBD or are at risk for colorectal disease, clinicians at the conference highlighted that these conditions are being seen more often and that treatment approaches have shifted toward personalized medicine and...
Cure8 found this source from academic.oup.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Research and clinical trials. Open the original article for the full details.
The article reports rising colorectal disease and IBD rates and describes modern shifts in treatment—topics that can affect screening, treatment options, and specialist care access for people with IBD or colorectal...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article...
Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
Cure8 found this source from eagletribune.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full details.
People with Crohn’s disease who have an ileostomy have limited noninvasive ways to monitor small-bowel inflammation. This study suggests measuring fecal calprotectin from ileostomy output could help detect postoperative...
Market reports highlight which companies and drug types are investing in Crohn's disease — that can signal upcoming therapies, trial activity, and availability. Mentions of trials (for example anti‑TL1A) may be of...
Cure8 found this source from sciencedirect.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. The original article is from msn.com.
Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Procedures and surgery. Open the original article for the full details.
People with both psoriasis and hidradenitis suppurativa appear to have higher overall morbidity and a greater observed risk of Crohn’s disease. Genetic findings suggest shared biological pathways that could affect how...
This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...
This story matters because it outlines a plausible way to extend the benefits of exclusive enteral nutrition (EEN) for Crohn's disease by using fecal microbiome transfer (FMT) to 'lock in' a healthier microbiome and...
This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in...
Cure8 could only read part of this source from eurekalert.org, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...
This study tests whether combining exclusive enteral nutrition with a follow-up fecal microbiome transfer can create a longer-lasting, less inflammatory gut microbiome — which could help maintain remission in Crohn’s...
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...
This suggests an existing antibiotic, vancomycin, may help a specific group of IBD patients who also have primary sclerosing cholangitis (PSC), including some who did not respond to other IBD treatments. If confirmed in...
This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.
Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed...
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from msn.com.
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from msn.com.
A noninvasive wearable that tracks inflammation markers could let people with IBD and their clinicians detect rising disease activity earlier and potentially act before symptoms develop. This may make monitoring less...
